financetom
Business
financetom
/
Business
/
National Bank Reviews EQB's Q2 Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank Reviews EQB's Q2 Results
May 30, 2024 11:57 AM

02:38 PM EDT, 05/30/2024 (MT Newswires) -- EQB reported Q2/24 adjusted EPS of $2.81 vs. NBF $2.71 and consensus $2.66.

EQB's better than expected Q2 2024 EPS was the result of top-line outperformance, notes National Bank. Results were highlighted by 10 bps of sequential NIM expansion (with some help from prepayment income).

Although the top-line performance was impressive, analyst Gabriel Dechaine says most bank investors are focusing on credit trends, which were a mixed bag. While there was a sequential decline in Gross Impaired Loans, after six consecutive quarters of increases, there was also a material amount of formations in the Equipment Finance book (i.e., GILs up 46% Q/Q), which contributed to loan losses exceeding both NBF and consensus forecasts by 30% and 10%, respectively.

The company has previously guided to improved credit performance in the second half. Reiteration of this outlook will be a key driver of the stock's near-term performance.

Maintain Sector Perform, $95 target.

Price: 87.15, Change: +8.32, Percent Change: +10.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UK's drug-cost watchdog recommends Alnylam's heart disease drug
UK's drug-cost watchdog recommends Alnylam's heart disease drug
Nov 20, 2025
Nov 21 (Reuters) - The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' ( ALNY ) heart disease drug, ensuring access for patients through the government health system in England and Wales, the company said on Friday. The country's drug regulator had approved the injectable drug, Amvuttra, in July to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in...
US consumer watchdog seeks to transfer cases to DOJ, citing funding, sources say
US consumer watchdog seeks to transfer cases to DOJ, citing funding, sources say
Nov 20, 2025
WASHINGTON, Nov 20 (Reuters) - The top U.S. consumer financial watchdog, which the White House refuses to fund, is seeking to move all remaining enforcement cases and litigation to the Department of Justice in light of the agency's dwindling financial resources, according to four people with knowledge of the matter. The Consumer Financial Protection Bureau, which said last week it...
Paramount, Comcast and Netflix submit bids for Warner Bros Discovery, source says
Paramount, Comcast and Netflix submit bids for Warner Bros Discovery, source says
Nov 20, 2025
Nov 20 (Reuters) - Warner Bros Discovery ( WBD ) has received preliminary buyout bids from rivals Paramount Skydance ( PSKY ) , Comcast ( CMCSA ) and Netflix ( NFLX ), a source familiar with the matter said on Thursday, kicking off a potential sale of the century-old Hollywood studio. The bids set the stage for a significant consolidation...
Paramount, Comcast and Netflix submit bids for Warner Bros Discovery, source says
Paramount, Comcast and Netflix submit bids for Warner Bros Discovery, source says
Nov 20, 2025
(Reuters) -Warner Bros Discovery has received preliminary buyout bids from rivals Paramount Skydance, Comcast and Netflix, a source familiar with the matter said on Thursday, kicking off a potential sale of the century-old Hollywood studio. The bids set the stage for a significant consolidation in the media industry and will determine the future of prized assets like HBO, the Warner...
Copyright 2023-2026 - www.financetom.com All Rights Reserved